Table 7 Statistical analysis of the results obtained using the proposed spectrofluorimetric and reported methods for analysis of the investigated drugs in pharmaceutical dosage forms
From: Spectrofluorimetric determination of certain antidepressant drugs in human plasma
Drug | Pharmaceutical dosage forms | Proposed method ± SD (n = 5) | Reported methods 8-10 ± SD (n = 5) |
|---|---|---|---|
Fluoxetine | Neurazine® tablets | 100.94 ± 1.390 | 100.53 ± 1.46 |
t = 0.45 e F = 1.09 e | |||
Sertraline | Thiozine® tablets | 100.18 ± 1.15 | 100.13 ± 1.68 |
t = 0.06 F = 2.13 | |||
Paroxetine | Stellasil® tablets | 100.01 ± 1.196 | 99.98 ± 0.95 |
t = 0.04 F = 1.59 | |||
Thioridazine | Tryptizol® tablets | 100.62 ± 0.663 | 100.22 ± 1.07 |
t = 0.71 F = 2.59 | |||
Amineptine | Survector® capsules | 100.14 ± 1.26 | 99.88 ± 1.59 |
t = 0.29 F = 1.59 |